$2.06
3.52% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US00461U1051
Symbol
ACRS

Aclaris Therapeutics, Inc. Stock price

$2.06
+0.50 32.05% 1M
+0.10 5.10% 6M
-0.42 16.94% YTD
+0.91 79.13% 1Y
-15.06 87.97% 3Y
-0.16 7.21% 5Y
-8.99 81.36% 10Y
-8.99 81.36% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.07 3.52%
ISIN
US00461U1051
Symbol
ACRS
Industry

Key metrics

Basic
Market capitalization
$223.2m
Enterprise Value
$123.4m
Net debt
positive
Cash
$99.8m
Shares outstanding
108.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.3 | 39.1
EV/Sales
7.4 | 21.6
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
70.6%
Return on Equity
-84.9%
ROCE
-90.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$16.8m | $5.7m
EBITDA
$-146.1m | $-78.5m
EBIT
$-146.6m | $-72.8m
Net Income
$-134.7m | $-56.9m
Free Cash Flow
$-46.7m
Growth (TTM | estimate)
Revenue
-47.6% | -69.5%
EBITDA
-119.7% | -52.3%
EBIT
-117.5% | -39.1%
Net Income
-129.5% | 56.9%
Free Cash Flow
28.3%
Margin (TTM | estimate)
Gross
10.2%
EBITDA
-870.1% | -1,374.2%
EBIT
-873.4%
Net
-802.0% | -996.8%
Free Cash Flow
-278.1%
More
EPS
$-1.1
FCF per Share
$-0.4
Short interest
6.6%
Employees
63
Rev per Employee
$300.0k
Show more

Is Aclaris Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Aclaris Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Aclaris Therapeutics, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Aclaris Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Aclaris Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
17 17
48% 48%
100%
- Direct Costs 15 15
18% 18%
90%
1.71 1.71
87% 87%
10%
- Selling and Administrative Expenses 22 22
18% 18%
132%
- Research and Development Expense 38 38
45% 45%
226%
-146 -146
120% 120%
-870%
- Depreciation and Amortization 0.56 0.56
40% 40%
3%
EBIT (Operating Income) EBIT -147 -147
118% 118%
-873%
Net Profit -135 -135
129% 129%
-802%

In millions USD.

Don't miss a Thing! We will send you all news about Aclaris Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aclaris Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris' Chief Executive Officer ...
Neutral
GlobeNewsWire
28 days ago
- Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Ant...
Neutral
GlobeNewsWire
about one month ago
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of IT
More Aclaris Therapeutics, Inc. News

Company Profile

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

Head office United States
CEO Neal Walker
Employees 63
Founded 2012
Website www.aclaristx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today